Abstract: The invention relates to pharmaceutical compositions comprising a PCSK9 inhibitor, such as an EGF(A) peptide, and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The invention further relates to processes for the preparation of such compositions, and their use in medicine.
| # | Name | Date |
|---|---|---|
| 1 | 202247029101.pdf | 2022-05-20 |
| 2 | 202247029101-STATEMENT OF UNDERTAKING (FORM 3) [20-05-2022(online)].pdf | 2022-05-20 |
| 3 | 202247029101-SEQUENCE LISTING(PDF) [20-05-2022(online)].pdf | 2022-05-20 |
| 4 | 202247029101-SEQUENCE LISTING [20-05-2022(online)].txt | 2022-05-20 |
| 5 | 202247029101-PRIORITY DOCUMENTS [20-05-2022(online)].pdf | 2022-05-20 |
| 6 | 202247029101-POWER OF AUTHORITY [20-05-2022(online)].pdf | 2022-05-20 |
| 7 | 202247029101-FORM 1 [20-05-2022(online)].pdf | 2022-05-20 |
| 8 | 202247029101-DRAWINGS [20-05-2022(online)].pdf | 2022-05-20 |
| 9 | 202247029101-DECLARATION OF INVENTORSHIP (FORM 5) [20-05-2022(online)].pdf | 2022-05-20 |
| 10 | 202247029101-COMPLETE SPECIFICATION [20-05-2022(online)].pdf | 2022-05-20 |
| 11 | 202247029101-FORM 18 [23-05-2022(online)].pdf | 2022-05-23 |
| 12 | 202247029101-FER.pdf | 2022-07-15 |
| 13 | 202247029101-RELEVANT DOCUMENTS [28-09-2022(online)].pdf | 2022-09-28 |
| 1 | SearchHistoryE_14-07-2022.pdf |